hoodb.com

康霈(6919)新藥CBL-514注射劑用於減少皮下脂肪之CBL-0204 Phase 2b臨床試驗取得最終統計結果，其試驗主要與次要療效指標在臨床與統計上皆達到顯著有效意義(12/11日股價521元，市值799.2億元)

|

You are leaving and open the following URL" of about "a 臨床試驗申請(12" news

news.google.com/rss/articles/CBMickFVX3lxTE1sV2U1bFM2YXlUbVhuek44X1dxM1duVU9hYkJNbzJ1RDZXYXY4WVhhUENNY2swSkdOSk91MUN4YnlLWjdpOVpLb2NiZFNodTJsMi1SQzVqSUlFdWRZOUZlcU5UMHdFaFFjcjZ1RGo0VVI3UQ?oc=5


Continue Opne >

a 臨床試驗申請(12: 康霈(6919)新藥CBL-514注射劑用於減少皮下脂肪之CBL-0204 Phase 2b臨床試驗取得最終統計結果，其試驗主要與次要療效指標在臨床與統計上皆達到顯著有效意義(12/11日股價521元，市值799.2億元)


More a 臨床試驗申請(12 news:



Warning: filemtime(): stat failed for aCache/aaa/gnews/CH/a 臨床試驗申請(12.xml in /var/www/hoodb/function.php on line 339
1736658738-
Warning: file_put_contents(aCache/aaa/gnews/CH//a 臨床試驗申請(12.xml): Failed to open stream: No space left on device in /var/www/hoodb/function.php on line 348

About a 臨床試驗申請(12

from
1736658738-1736286097

Warning: filemtime(): stat failed for aCache/search/ch/a 臨床試驗申請(12 in /var/www/hoodb/function.php on line 339
1736658738-

a 臨床試驗申請(12, 康霈(6919)新藥CBL-514注射劑用於減少皮下脂肪之CBL-0204 Phase 2b臨床試驗取得最終統計結果，其試驗主要與次要療效指標在臨床與統計上皆達到顯著有效意義(12/11日股價521元，市值799.2億元) 2022 a 臨床試驗申請(12

康霈(6919)新藥CBL-514注射劑用於減少皮下脂肪之CBL-0204 Phase 2b臨床試驗取得最終統計結果，其試驗主要與次要療效指標在臨床與統計上皆達到顯著有效意義(12/11日股價521元，市值799.2億元)

Choose Your Country or Region


Back to Top



康霈(6919)新藥CBL-514注射劑用於減少皮下脂肪之CBL-0204 Phase 2b臨床試驗取得最終統計結果，其試驗主要與次要療效指標在臨床與統計上皆達到顯著有效意義(12/11日股價521元，市值799.2億元)

Copyright © 2020-2021 hoodb.com. All Rights Reserved.